The calculated risk of developing hepatoma (hepatocellular carcinoma-HCC) has been reported to be 61 times greater for patients with acute intermittent porphyria (AlP) than for the general population, based on data from Scandinavia where the prevalence of AlP is unusually high. 1 • 2 HCC was reported to be the cause of death in 8% of one series of Finnish patients with acute porphyria.! The reason for this is unclear, but it could be related to the disturbed hepatocyte metabolism in these patients. The prevalence of cirrhosis is unknown in acute porphyria, but might be expected to be lower than in the general population, as porphyries are advised to avoid alcohol. Several mechanisms by which porphyria increases the risks of HCC have been suggested." Serum alpha-fetoprotein (AFP) concentration is a commonly used screening test for hepatoma, being raised in around 80010 of cases.! It can also be elevated in a variety of other liver diseases such as acute hepatitis, chronic active hepatitis, cirrhosis and metastatic cancer. Non-hepatic conditions associated with high AFP include pregnancy, non-metastatic gastro-intestinal cancer, testicular teratoma, congestive cardiac failure, chronic lymphatic leukaemia and inherited metabolic defects such as hereditary tyrosinaemia. S To investigate whether the acute hepatic porphyrias themselves raise AFP, and might thereby cause a false positive test for hepatoma, we measured AFP in patients with acute hepatic porphyria.
METHODS

Forty-four patients with acute hepatic porphyria in remission who were having blood taken for
Correspondence: Dr Simon Dover, Gastroenterology Unit, LevelS, Gartnavel General Hospital, Glasgow Gl2 OYN, UK. other reasons, and in whom there was no reason to suspect the presence of a hepatoma, were examined. All of the patients had acute intermittent porphyria, confirmed by a low erythrocyte porphobilinogen deaminase activity (normal adult range: men 24-49, women 30-54 nmol porphyrin formed/mL erythrocytes/ hour)." Six of these patients also had an AFP measurement made during a porphyric crisis.
AFP was measured by an immunoenzymometric assay on an Abbott IMX analyser (Abbott Diagnostics, Maidenhead, UK). Using this assay the manufacturers report that 99% of healthy subjects had a serum AFP concentration of less than or equal to 7·1 kU/L. In our laboratory concentrations of less than or equal to 5 kU/L are classified as normal. Concentrations of greater than 5 kU/L but less than 10 kU/L are considered equivocal, and follow up is advised as appropriate clinically. Table 1 were obtained from the 44 patients studied in remission. All the patients had AlP. There were 28 females and 16 males. The mean age was 37, range 14-63. Six of the patients had AFP measured both in remission and in attack. In four cases there was no difference, and in two cases differences of only 1 and 2 kU/L, respectively, higher in attack, though in neither case did it climb above 5 kU/L.
RESULTS
The values shown in
DISCUSSION
Serum AFP concentration is a commonly used test for HCC. It can however be elevated in a variety of other hepatic and non-hepatic disorders. HCC is more common in patients with acute hepatic porphyria than in the general population. Efforts at early detection of these tumours in porphyria patients have been advocated," and a programme has started in Sweden (C Andersson, personal communication). Screening for hepatoma in other high risk patient groups depends on AFP measurements," Now that the acute porphyrias themselves seldom cause premature death, associated diseases such as HCC will become an increasing problem.l The acute hepatic porphyrias are metabolic liver diseases associated with the excretion of abnormal products of metabolism. In order to assess the significance of a raised serum AFP concentration in acute hepatic porphyria, we need to establish whether the acute hepatic porphyrias are themselves associated with an elevated AFP in the absence of HCC. No porphyria patient was found to have an AFP above the normal range. A raised AFP in a patient with AlP cannot therefore be attributed to the porphyria, and another cause, such as a hepatocellular carcinoma should be considered.
Ann C/in Biochem 1994: 31 CONCLUSION While this study does not attempt to validate AFP as a diagnostic or screening test for HCC in AlP, it does confirm that elevated serum AFP concentrations cannot be attributed to the metabolic changes associated with porphyria. Porphyric patients with elevated AFP should be further investigated for underlying HCC.
